DarioHealth (NASDAQ:DRIO) Rating Increased to Hold at Wall Street Zen

DarioHealth (NASDAQ:DRIO) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Sunday.

DRIO has been the topic of several other reports. Stifel Nicolaus set a $16.00 target price on DarioHealth in a report on Friday, November 14th. Cowen reiterated a “hold” rating on shares of DarioHealth in a research report on Friday, November 14th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of DarioHealth in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, DarioHealth has an average rating of “Hold” and an average price target of $32.00.

DarioHealth Trading Down 10.1%

DRIO stock opened at $11.54 on Friday. The stock has a market capitalization of $78.10 million, a price-to-earnings ratio of -1.03 and a beta of 1.08. DarioHealth has a twelve month low of $5.93 and a twelve month high of $31.00. The firm’s fifty day simple moving average is $13.06 and its two-hundred day simple moving average is $12.42. The company has a quick ratio of 4.02, a current ratio of 4.55 and a debt-to-equity ratio of 0.41.

Institutional Inflows and Outflows

An institutional investor recently raised its position in DarioHealth stock. XTX Topco Ltd raised its stake in shares of DarioHealth Corp. (NASDAQ:DRIO) by 229.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 62,511 shares of the company’s stock after acquiring an additional 43,513 shares during the period. XTX Topco Ltd owned approximately 0.14% of DarioHealth worth $42,000 as of its most recent SEC filing. Institutional investors own 33.39% of the company’s stock.

About DarioHealth

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.